Rifaximin

Rifaximin

• CAS Number: 80621-81-4
• UNSPSC Description: Rifaximin, a gastrointestinal-selective antibiotic, binds the β-subunit of bacterial DNA-dependent RNA polymerase, resulting in inhibition of bacterial RNA synthesis. Rifaximin susceptibility is higher against Gram-positive strains (MIC: 0.03-5 mg/ml) compared to Gram-negative bacteria (MIC: 8-50 mg/mL)[1][2].
• Target Antigen: Antibiotic; Bacterial; DNA/RNA Synthesis
• Type: Reference compound
• Related Pathways: Anti-infection;Cell Cycle/DNA Damage
• Field of Research: Infection; Cancer
• Assay Protocol: https://www.medchemexpress.com/Rifaximin.html
• Purity: 99.88
• Solubility: DMSO : ≥ 50 mg/mL
• Smiles: O=C1C2=C(O[C@@]1(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@@H](O)[C@@H](C)/C=C/C=C(C)\C3=O)C)O)C)OC(C)=O)C)OC)C)C(C)=C(O)C4=C2C5=C(C(N3)=C4O)N6C(C=C(C)C=C6)=N5
• Molecular Weight: 785.88
• References & Citations: [1]Veronica Ojetti, et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):675-82.|[2]Giuseppe Esposito,et al. Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. Int J Oncol. 2016 Aug;49(2):639-45.|[3]Stefano Fiorucci,et al.Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66(4):246-56.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched